As many as one third of newly diagnosed multiple myeloma (MM) cases are classified as high risk, with widely varying rates of ...

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses ...

"We are well aware that four-drug regimens with anti-CD38 monoclonal antibodies, lenalidomide, proteasome inhibitors, and dexamethasone are a standard for newly diagnosed multiple myeloma, ...

The global rise in obesity is staggering. Obesity has doubled in over 70 nations within a span of a mere four decades.

Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...

Cevostamab showed a 93% MRD-negative complete response rate at 1 year post CAR T-cell therapy in heavily pretreated multiple ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

Iberdomide combined with standard therapies showed a statistically significant improvement in minimal residual disease (MRD) ...

Tamara Mobley's persistent back pain led to a multiple myeloma diagnosis after initial dismissive medical consultations. Her ...

Collaboration between community practices and academic institutions is crucial for administering bispecific antibodies, with ...

While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...

TORONTO -- Linvoseltamab (Lynozyfic) appeared effective in patients with high-risk smoldering multiple myeloma (HR-SMM), according to preliminary phase II trial data. With a median follow-up of 3.9 ...